文献速递心脑血管急症

急诊科晕厥评估后的个体化风险预测

Personalised risk prediction following emergency department assessment for syncope.
PubMed 文献 · Emerg Med J · 2021-11-05
一句话结论基于加拿大晕厥风险评分(CSRS)的个体化风险预测可指导急诊晕厥处置:极低/低危患者可出院,中危需讨论,高危应住院。

该研究汇总加拿大晕厥风险评分(CSRS)推导与验证两个前瞻性队列,纳入2010至2018年11个加拿大急诊科的8233例成人晕厥患者,计算CSRS校准与区分度及30天严重结局风险。30天严重结局发生率为3.6%(95%CI 3.2%至4.0%),校准斜率为1.0,AUC为0.88(95%CI 0.87至0.91)。观察风险从极低危组(CSRS -3至-2)的0.3%(95%CI 0.2%至0.5%)升至极高危组(CSRS≥+6)的42.7%(95%CI 35.0%至50.7%),趋势检验p<0.001。作者据此开发在线计算器与图示决策辅助工具,并提出极低/低危患者可出院、中危需讨论、高危应住院。

要点

  • 极低危及低危患者(CSRS -3至0)30天严重结局≤1.0%,仅1例脓毒症死亡,无室性心律失常,作者认为可出院。
  • 中危患者(CSRS +1至+3)30天严重结局7.8%,死亡<1%,作者认为需与患者讨论检查与去向。
  • 高危/极高危患者(CSRS +4至+11)30天严重结局>20%,死亡4%至6%,作者认为应住院。
  • CSRS区分度AUC 0.88(95%CI 0.87至0.91),校准斜率1.0,观察风险随CSRS升高而增加(趋势检验p<0.001)。
  • 在线计算器与图示决策辅助工具可用于与患者讨论(https://teamvenk.com/csrs)。

适用人群与场景

  • 2010至2018年在11个加拿大急诊科前瞻性纳入的成人(≥16岁)晕厥患者。

诊断标准与关键阈值

  • 加拿大晕厥风险评分(CSRS)风险分组:极低危 -3至-2,低危 -1至0,中危 +1至+3,高危/极高危 +4至+11(极高危为≥+6)。

处置流程与药物剂量

  • 作者认为极低危和低危患者(CSRS -3至0)可出院。
  • 作者认为中危患者(CSRS +1至+3)需与患者讨论检查与去向。
  • 作者认为高危患者应住院。
  • 在线计算器与图示决策辅助工具可用于协助与患者讨论。

研究设计与关键结果

  • 研究类型:汇总两项前瞻性队列(CSRS推导与验证队列)数据的分析;样本量8233例;11个加拿大急诊科;人群为成人(≥16岁)晕厥患者。
  • 30天严重结局发生率3.6%(95%CI 3.2%至4.0%,295/8233)。
  • 校准斜率1.0,AUC 0.88(95%CI 0.87至0.91)。
  • 30天观察风险从极低危组(CSRS -3至-2)0.3%(95%CI 0.2%至0.5%)升至极高危组(CSRS≥+6)42.7%(95%CI 35.0%至50.7%),Cochrane-Armitage趋势检验p<0.001。
  • 极低危及低危患者(评分-3至0)中≤1.0%发生严重结局,1例脓毒症死亡,无室性心律失常。
  • 中危患者(评分+1至+3)中7.8%发生严重结局,死亡<1%。
  • 高危/极高危患者(评分+4至+11)中>20%发生严重结局,死亡4%至6%。

证据类型、等级与局限

  • 证据类型:基于两项前瞻性队列的汇总分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为极低危和低危患者(CSRS -3至0)可出院。
  • 作者认为中危患者(CSRS +1至+3)需与患者讨论检查与去向。
  • 作者认为高危患者应住院。
  • 在线计算器与图示决策辅助工具可用于协助与患者讨论。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Published risk tools do not provide possible management options for syncope in the emergency department (ED). Using the 30-day observed risk estimates based on the Canadian Syncope Risk Score (CSRS), we developed personalised risk prediction to guide management decisions.

METHODS: We pooled previously reported data from two large cohort studies, the CSRS derivation and validation cohorts, that prospectively enrolled adults (≥16 years) with syncope at 11 Canadian EDs between 2010 and 2018. Using this larger cohort, we calculated the CSRS calibration and discrimination, and determined with greater precision than in previous studies the 30-day risk of adjudicated serious outcomes not identified during the index ED evaluation depending on the CSRS and the risk category. Based on these findings, we developed an on-line calculator and pictorial decision aids.

RESULTS: 8233 patients were included of whom 295 (3.6%, 95% CI 3.2% to 4.0%) experienced 30-day serious outcomes. The calibration slope was 1.0, and the area under the curve was 0.88 (95% CI 0.87 to 0.91). The observed risk increased from 0.3% (95% CI 0.2% to 0.5%) in the very-low-risk group (CSRS -3 to -2) to 42.7% (95% CI 35.0% to 50.7%), in the very-high-risk (CSRS≥+6) group (Cochrane-Armitage trend test p<0.001). Among the very-low and low-risk patients (score -3 to 0), ≤1.0% had any serious outcome, there was one death due to sepsis and none suffered a ventricular arrhythmia. Among the medium-risk patients (score +1 to+3), 7.8% had serious outcomes, with <1% death, and a serious outcome was present in >20% of high/very-high-risk patients (score +4 to+11) including 4%-6% deaths. The online calculator and the pictorial aids can be found at: https://teamvenk.com/csrs CONCLUSIONS: 30-day observed risk estimates from a large cohort of patients can be obtained for management decision-making. Our work suggests very-low-risk and low-risk patients may be discharged, discussion with patients regarding investigations and disposition are needed for medium-risk patients, and high-risk patients should be hospitalised. The online calculator, accompanied by pictorial decision aids for the CSRS, may assist in discussion with patients.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Thiruganasambandamoorthy V, Yan JW, Rowe BH, et al. Personalised risk prediction following emergency department assessment for syncope. Emerg Med J. 2021. PMID: 34740890. doi:10.1136/emermed-2020-211095

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。